A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage Baris Ata, M.D., M.Sc., Seang Lin Tan, M.D., M.B.A., Fady Shehata, M.B., B.Ch., M.Sc., Hananel Holzer, M.D., William Buckett, M.D. Fertility and Sterility Volume 95, Issue 3, Pages 1080-1085.e2 (March 2011) DOI: 10.1016/j.fertnstert.2010.12.021 Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Live birth rate with IVIG in women with recurrent miscarriage. Fertility and Sterility 2011 95, 1080-1085.e2DOI: (10.1016/j.fertnstert.2010.12.021) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Figure 2 Live birth rates stratified by type of miscarriage. (A) Primary recurrent miscarriage. (B) Secondary recurrent miscarriage. Fertility and Sterility 2011 95, 1080-1085.e2DOI: (10.1016/j.fertnstert.2010.12.021) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Figure 3 Live birth rate stratified by treatment start time. (A) Before pregnancy. (B) After pregnancy. Fertility and Sterility 2011 95, 1080-1085.e2DOI: (10.1016/j.fertnstert.2010.12.021) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Auxiliary analysis: live birth rate in women with secondary recurrent miscarriage, including trials recruiting women with antiphospholipid antibodies. Christiansen et al. (10) includes only women who had recurrent miscarriage after a prior live birth. Fertility and Sterility 2011 95, 1080-1085.e2DOI: (10.1016/j.fertnstert.2010.12.021) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Auxiliary analysis: live birth rates in trials comparing IVIG and saline. Fertility and Sterility 2011 95, 1080-1085.e2DOI: (10.1016/j.fertnstert.2010.12.021) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions